Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Objective Although sorafenib, a molecular targeted agent, has survival benefits for advanced
hepatocellular carcinoma (HCC) patients, its disease control rate remains limited. To explore …

Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality.
Despite the widespread adoption of sorafenib as the standard HCC treatment, its efficacy is …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary
neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

The approval of a multitargeted receptor tyrosine kinase inhibitor, sorafenib, with activity
against vascular endothelial growth factor receptor-2 and-3, Raf-1 and B-Raf, platelet …

Sunitinib malate is an oral, multitargeted receptor tyrosine kinase inhibitor of VEGF receptors
1, 2 and 3; PDGF receptors α and β, and other receptor tyrosine kinases implicated in tumor …